Social media

Robust NMA depends on systematic feasibility assessment, careful network construction and rigorous model evaluation. The paper details the workflow from literature review to treatment ranking, highlighting the importan...

Attending World Vaccine Congress? Stop by booth \#222 to meet the ICON team to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑development solu...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth \#31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small mole...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth #31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small molec...

2026 marks the first real entry of high risk medical devices into EU JCAs. From implantable prosthetics to active implantable devices, 15 categories have been identified as early candidates. This shift represents a maj...

2026 marks the first real entry of high risk medical devices into EU JCAs. From implantable prosthetics to active implantable devices, 15 categories have been identified as early candidates. This shift represents a maj...

At the PharmaSUG India Single Day Event on 11 April, hosted at the Eli Lilly office in Bangalore, ICON will be represented by Gomathi S, Statistical Programmer I. Gomathi will present the poster titled “Evolving submiss...

At the PharmaSUG India Single Day Event on 11 April, hosted at the Eli Lilly office in Bangalore, ICON will be represented by Gomathi S., Statistical Programmer I. Gomathi will present the poster titled “Evolving submis...

Today \@WVCUS, join ICON plc experts for a working group discussion on ‘Vaccine trials: How AI shifts execution from static plans to living systems’. Learn more at 11:40 am: https://ow.ly/9Uk050Yr8VL

ICON’s Patient Centred Outcomes team delivered strong progress in 2025. – Over 45 specialists across Europe and North America – Twelve peer‑reviewed papers and two webinars – Methodological depth across COA strategy, psy...

ICON’s Patient Centred Outcomes team delivered strong progress in 2025. – Over 45 specialists across Europe and North America – Twelve peer‑reviewed papers and two webinars – Methodological depth across COA strategy, psy...

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...